postpartum%20depression
POSTPARTUM DEPRESSION

Postpartum depression is the occurrence of a major depressive episode within 4 weeks following delivery or up to a year after childbirth.

It may peak at 2-4 weeks and 10-14 weeks after childbirth.

Symptoms are similar to that of major depression but with additional features distinctive of the postpartum period like feelings of being overwhelmed and inadequate as a parent.

Postpartum Depression Drug Information

Drug Information

Indication: Depression including depression w/ associated anxiety. Generalized anxiety disorder (GAD) including long-term ...

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety. Obsessive compuls...

Indication: Depression & prevention of relapse/recurrence; panic disorder (PD) w/ or w/o agoraphobia; obsessive-compul...

Indication: Depression, obsessive-compulsive disorder, premenstrual dysphoric disorder (PMDD).

Indication: Symptomatic treatment of depression w/ or w/o anxiety. Obsessive compulsive disorder, pre-menstrual dysphoric ...

Indication: Depression. Bulimia nervosa.

Indication: Major depressive disorder, panic disorder w/ or w/o agoraphobia, premenstrual dysphoric disorder, social anxie...

Indication: Symptomatic treatment of depression including depression accompanied by anxiety symptoms, in patients w/ or w/...

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety in patients w/ or ...

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.